Myrbetriq is a prescription medicine for adults approved by the U.S. Food and Drug Administration (FDA) to treat the overactive bladder symptoms of urgency, frequency, and leakage. Myrbetriq was shown in studies to be effective in treating OAB symptoms of urgency, frequency and leaks within the first 4 to 8 weeks.

Myrbetriq (mirabegron) is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Myrbetriq® is a registered trademark of Astellas Pharma Inc.

MYRBETRIQ is a prescription medicine for adults that can be used alone or with solifenacin succinate to treat the following symptoms due to a condition called overactive bladder: Urge urinary incontinence: a strong need to urinate with leaking or wetting accidents. Urgency: a strong need to urinate right away.

Myrbetriq has an average rating of 4.2 out of 10 from a total of 82 reviews for the treatment of Urinary Incontinence. 27% of reviewers reported a positive experience, while 55% reported a negative experience.

It's best to take Myrbetriq at around the same time of day. This helps maintain a steady level of the drug in your body so Myrbetriq can work effectively. Choose a dosing time that works for you and try to stick to it. Myrbetriq extended-release tablets should be swallowed whole with a drink of water.

Years of research and testing are needed to ensure that brand-name drugs are safe and effective. This testing can make the drugs expensive. The manufacturer of a brand-name drug can sell the drug for up to 20 years. After that, other drugmakers can create generic versions.

Myrbetriq (mirabegron) is a beta-3 adrenergic agonist indicated for the treatment of the overactive bladder (OAB) condition. It was developed by Japan's Tokyo-based pharmaceutical company, Astellas Pharma.

Myrbetriq is the #1 prescribed* branded medication for OAB.

Effectiveness for overactive bladder Myrbetriq is an effective treatment for OAB in adults. It helps reduce the number of times you urinate per day and the number of incontinence episodes you have. American Urological Association guidelines recommend Myrbetriq as a treatment option for OAB in adults.

The FDA approval of Myrbetriq for adults was based on the results of three, 12-week, double-blind, randomized, placebo-controlled, parallel group, multicenter clinical trials in subjects with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Myrbetriq has an average rating of 4.2 out of 10 from a total of 82 reviews for the treatment of Urinary Incontinence. 27% of reviewers reported a positive experience, while 55% reported a negative experience.